Post-doctoral position in gene therapy of muscle diseases
The Gene-based therapies for congenital myopathies (CMyo) team directed by Ana Buj Bello in the INTEGRARE unit ("Integrated genetic approaches for the treatment of Rare genetic diseases", also identified as UMR_S951) of Genethon focuses on the development of innovative gene therapies for neuromuscular disorders based on the understanding of the underlying genetic defects and pathophysiology. Its translational research is currently focused on the exploration and optimization of new therapeutic approaches for orphan neuromuscular diseases using AAV vector technology and genome editing.
The current project aims at developing a novel gene therapy for a congenital myopathy by taking advantage on recent advances in capsid engineering and transgene expression regulation. Several AAV vectors will be generated and evaluated in a mouse model available in our laboratory. The candidate will be in charge of designing vectors and assessing their efficacy in mice by molecular, biochemical and histological techniques. In addition, the candidate will coordinate the work with other teams.
Fixed-term contract of 2 years, starting no later than October 1st, 2022.
- PhD in molecular or cell biology, physiology or other relevant life sciences obtained in 2019, 2020 or 2021.
- Expertise in molecular and cellular biology techniques.
- Experience in gene therapy, AAV vectors or muscle studies will be a plus.
- Ability to conduct the project independently and to work with other team members.
- Excellent organizational skills, rigor and reliability.
- Good oral, written and presentation skills.